newsfilter
← Latest News
GlobeNewswire·

NextCure Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024

Of the evaluable ICI-naïve MSS/MSI-L CRC patients without liver metastasis, there were 2 confirmed ongoing PRs and a disease control rate of 51%Of the 7 evaluable ovarian cancer patients, there were 3 PRs and a disease